SEARCH

SEARCH BY CITATION

References

  • 1
    Corbella J. The History of the Hospital of Barcelona. 100 Years: 1906-2006. Barcelona, Spain: Grupo Ars XXI de Comunicación SL; 2006.
  • 2
    Bruguera M. The Hepatology Unit of Hospital Clinic, Barcelona. The history of an adventure. Barcelona, Spain: Collegi Oficial de Metges de Barcelona; 2003.
  • 3
    Pérez-Ayuso RM, Arroyo V, Planas R, Gaya J, Bory F, Rimola A, et al. Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites, Relationship between the diuretic response and the activity of the renin aldosterone system. Gastroenterology 1983; 84: 961968.
  • 4
    EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53: 397417.
  • 5
    Kravetz D, Bosch J, Terés J, Bruix J, Rimola A, Rodés J. Comparison of intravenous somatostain and vasopressin infusions in treatment of acute variceal hemorrhage. HEPATOLOGY 1984; 4: 442446.
  • 6
    Bosch J, Kravetz D, Rodés J. Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver. Comparison with vasopressin. Gastroenterology 1981; 80: 518525.
  • 7
    de Franchis R, Baveno V Faculty. Revising consensus in portal hypertension: Report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2010; 53: 762768.
  • 8
    Ginés P, Arroyo V, Quintero E, Planas R, Bory F, Cabrera J, et al. Comparison of paracentesis and diuretics in the treatment of cirrhosis with tense ascites. Results of a randomized study. Gastroenterology 1987; 93: 234241.
  • 9
    Tito L, Ginés P, Arroyo V, Planas R, Panés J, Rimola A, et al. Total paracentesis associated with intravenous albumin in the management of patients with cirrhosis and ascites. Gastroenteroloy 1990; 98: 146151.
  • 10
    Titó L, Rimola A, Gines P, Llach J, Arroyo V, Rodés J. Recurrence of spontaneous bacterial peritonitis in cirrhosis. Frequency and predictive factors. HEPATOLOGY 1988; 8: 2731.
  • 11
    Ginès P, Rimola A, Planas R, Vargas V, Marco F, Almela M, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis. Results of a double-blind, placebo controlled trial. HEPATOLOGY 1990; 12: 716724.
  • 12
    Lebrec D, Poynard T, Hillon P, Benhamou JP. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis. A controlled study. N Engl J Med 1981; 305: 13711374.
  • 13
    Pascal JP, Cales P, Propranolol in the prevention of first upper gastrointestinal tract hemorrhage in patients with cirrhosis of the liver and esophageal varices. N Engl J Med 1987; 317: 856861.
  • 14
    Conn HO, Grace ND, Bosch J, Groszmann RJ, Rodés J, Wright SC, et al. Propranolol in the prevention of the first hemorrhage from esophagogastric varices. A multicenter randomized clinical trial. The Boston-New Haven-Barcelona Portal Hypertension Study Group. HEPATOLOGY 1991; 13: 902912.
  • 15
    Follo A, Llovet JM, Navasa M, Planas R, Forns X, Francitorra A, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. HEPATOLOGY 1994; 20: 14951501.
  • 16
    Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341: 403409.
  • 17
    Fernández J, Monteagudo J, Bargallo X, Jiménez W, Bosch J, Arroyo V, et al. A randomized unblinded pilot study comparing albumin versus hydroxethyl starch in spontaneous bacterial peritonitis. HEPATOLOGY 2005; 42; 627634.
  • 18
    Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral arterial vasodilatation hypothesis. A proposal for the initiation of renal sodium and water retention in cirrhosis. HEPATOLOGY 1988; 8: 11511157.
  • 19
    Uriz J, Gines P, Cardenas A, Sort P, Jiménez W, Salmerón JM, et al. Terlipressin plus albumin infusion: an effecitve and safe therapy of hepatorenal syndrome. J Hepatol 2000; 33: 4348.
  • 20
    Martin-Llahí M, Pepín MN, Guevara M, Díaz F, Torre A, Monescillo A, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008; 134: 13521359.
  • 21
    Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 17341739.
  • 22
    Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. HEPATOLOGY 2010; 42: 12081236.
  • 23
    Jimenez W, Martinez A, Arroyo V, Bruix J, Rimola A, Gaya J, et al. Temporal relationship between hyperaldosteronism, sodium retention and ascites formation in rats with experimental cirrhosis. HEPATOLOGY 1985; 5: 245250.
  • 24
    Ginès P, Cárdenas A, Arroyo V, Rodés J. Management of cirrhosis and ascites. N Engl J Med 2004; 350: 16461654.
  • 25
    Ginès P, Schrier RW. Renal failure in cirrhosis. N Engl J Med 2009; 361: 12791290.
  • 26
    Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378390.
  • 27
    Garcia-Pagan JC, Caca K, Bureau C, Laleman W, Appenrodt B, Luca A, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med 2010; 362: 23702379.
  • 28
    European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245264.
  • 29
    European Association for the Study of the Liver. EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol 2009; 51: 237267.
  • 30
    Hennes EM, Zeniya M, Czaja AJ, Parés A, Dalekos GN, Krawitt EL, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. HEPATOLOGY 2008; 48: 169176.